HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial
vTv discovered small molecule RAGE inhibitor is being developed by Cantex under worldwide development and commercialization agreement HIGH POINT, N.C. , June 16, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of
vTv discovered small molecule RAGE inhibitor being developed by Cantex under worldwide development and commercialization agreement HIGH POINT, N.C. , May 24, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an
HIGH POINT, N.C. , May 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter
Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetes Biotech industry and Wall Street veteran Steven Tuch appointed Executive Vice President and Chief Financial Officer Biotech industry veteran Elizabeth Keiley
HIGH POINT, N.C. , Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Elizabeth (Betzy) Keiley as Executive Vice
Steven Tuch , Chief Financial Officer HIGH POINT, N.C. , Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of
Company on-track to initiate Phase 3 clinical trials of TTP399 in the first quarter of 2023 Industry veteran Paul Sekhri joins the Company as President, Chief Executive Officer, and member of the Board of Directors Agreements with CinRx Pharma and a subsidiary to provide additional capital and
Paul Sekhri appointed as President, Chief Executive Officer and Board member. Entered into agreements with CinRx Pharma and a subsidiary to purchase $10 million in stock and to leverage CinRx’s industry experience to collaborate in overseeing TTP399 clinical trials.
HIGH POINT, N.C. , July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced that Paul Sekhri will lead the company as President and Chief